Office of the Chief Science Officer Mail Stop: 6502A Ottawa, Ontario K1A OK9 Canada July 31, 2014 Dr. Nick Vahanian BioProtection Systems Corporation, Iowa State University Research Park Ames, Iowa, 50010 USA Dear Dr. Vahanian, Re: Amendment to the...Newlink Genetics Corp • November 10th, 2014 • Pharmaceutical preparations
Canada and BioProtection Systems Corporation (BPSC) have executed a License Agreement dated May 04, 2010, under which Canada granted a license to BPS to commercialize the technology developed by Canada known as the recombinant vesicular stomatitis virus vaccine for viral hemorrhagic fevers (rVSV). For greater clarity, the Parties hereby agree to amend the License Agreement to define the scope of the “Licensed Rights” as follows:
LICENSE AGREEMENT AMENDMENTLicense Agreement • November 10th, 2014 • Newlink Genetics Corp • Pharmaceutical preparations
The following is an amendment to Exhibit A of the License Agreement between Medical College of Georgia and NewLink Genetics previously executed on September 13th, 2005. The purpose of this amendment is to explicitly list patent applications filed previously to the execution of this Agreement as continuations of [*], and which were unintentionally omitted in the original Exhibit A. These missing patent applications are: [*] and [*] and [*].
License and Collaboration AgreementLicense and Collaboration Agreement • November 10th, 2014 • Newlink Genetics Corp • Pharmaceutical preparations • New York
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is made as of October 16, 2014 (the “Execution Date”), by and between NewLink Global, an exempted company organized and existing under the laws of the Cayman Islands, having its principal place of business at Grand Cayman, Cayman Islands (“NGC”), NewLink Genetics Corporation, a corporation organized and existing under the laws of Delaware, having its principal place of business at 2503 South Loop Drive, Ames, Iowa 50010 (“NLNK”) (NGC and NLNK collectively, “NewLink”), and Genentech, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 USA (“GNE”), and F. Hoffmann-La Roche Ltd, a corporation organized and existing under the laws of Switzerland, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). NewLink and Genentech are sometim
Amendment to Development and Manufacturing Terms and ConditionsTerms and Conditions • November 10th, 2014 • Newlink Genetics Corp • Pharmaceutical preparations • New York
This Amendment to Development and Manufacturing Terms and Conditions (this “Amendment”) is made and entered into as of September 30, 2014 by and among NewLink Genetics Corporation, a Delaware corporation (“Customer”), and WuXi AppTec, Inc., a Delaware corporation (“WuXi AppTec,” and collectively with the Customer, the “Parties”).
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 10th, 2014 • Newlink Genetics Corp • Pharmaceutical preparations
This Amendment to License Agreement (“Amendment”) is effective as of July 10, 2014 (the “Amendment Effective Date”), by and between Georgia Regents Research Institute, Inc. (formerly known as Georgia Health Sciences University Research Institute, Inc. which was formerly known as Medical College of Georgia Research Institute, Inc.) (“GRRI”) and NewLink Genetics Corporation (“NewLink”). GRRI and NewLink are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
